Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040766 | 0.80 | TNFRSF1A (0.47) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL6040761 | 0.80 | TNFRSF1A (0.47) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL6040675 | 0.80 | ERN1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6040679 | 0.79 | TNFRSF1A (0.52) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5560733 | 0.77 | TNFRSF1A (0.57) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6040822 | 0.76 | MAPT (0.42) | NPC1RAB9AALDH1A1TSHRMAPK1 | |
| SCHEMBL1049736 | 0.75 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL856031 | 0.75 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL6040757 | 0.74 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL5559926 | 0.73 | ERN1 (0.49) | ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040181075-A1 | Process of making chalcone derivatives | GENERAL ELECTRIC COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056727-A2 | PROCESS OF MAKING CHALCONE DERIVATIVES | ATHEROGENICS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | NPC1 40/4885RAB9A 1137/4885SMN1; SMN2 2931/4885 |
| US-20040181075-A1 | Process of making chalcone derivatives | CYP2B6, LSS, CYP2E1 | NPC1 1311/4885RAB9A 3448/4885SMN1; SMN2 4274/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | NPC1 22/4885RAB9A 998/4885SMN1; SMN2 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.